Selected research
Industry Research
OTC Anti-Infective Medications Industry Research Report 2026
Market perspective
The global OTC Anti-Infective Medications market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the OTC Anti-Infective Medications market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the OTC Anti-Infective Medications market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the OTC Anti-Infective Medications market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of OTC Anti-Infective Medications include Abbott, Sanofi, Novartis, Merck, Roche, Pfizer, GlaxoSmithKline, Optimer Pharmaceuticals and Novabay Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global OTC Anti-Infective Medications market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to OTC Anti-Infective Medications.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
OTC Anti-Infective Medications Market by Company
Abbott
Sanofi
Novartis
Merck
Roche
Pfizer
GlaxoSmithKline
Optimer Pharmaceuticals
Novabay Pharmaceuticals
NanoViricides
MerLion Pharma
Bristol-Myers Squibb
Basilea Pharmaceutica
OTC Anti-Infective Medications Segment by Type
Antiseptic
Antiparasitics
Antifungals
OTC Anti-Infective Medications Segment by Application
E-Commerce
Drug Stores
Hospital Pharmacies
OTC Anti-Infective Medications Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OTC Anti-Infective Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of OTC Anti-Infective Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OTC Anti-Infective Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of OTC Anti-Infective Medications companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antiseptic
- Antiparasitics
- Antifungals
Applications
- E-Commerce
- Drug Stores
- Hospital Pharmacies
Companies covered
- Abbott
- Sanofi
- Novartis
- Merck
- Roche
- Pfizer
- GlaxoSmithKline
- Optimer Pharmaceuticals
- Novabay Pharmaceuticals
- NanoViricides
- MerLion Pharma
- Bristol-Myers Squibb
- Basilea Pharmaceutica
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 OTC Anti-Infective Medications by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Antiseptic
- 2.2.3 Antiparasitics
- 2.2.4 Antifungals
- 2.3 OTC Anti-Infective Medications by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 E-Commerce
- 2.3.3 Drug Stores
- 2.3.4 Hospital Pharmacies
- 2.4 Assumptions and Limitations
3 OTC Anti-Infective Medications Breakdown Data by Type
- 3.1 Global OTC Anti-Infective Medications Historic Market Size by Type (2021-2026)
- 3.2 Global OTC Anti-Infective Medications Forecasted Market Size by Type (2027-2032)
4 OTC Anti-Infective Medications Breakdown Data by Application
- 4.1 Global OTC Anti-Infective Medications Historic Market Size by Application (2021-2026)
- 4.2 Global OTC Anti-Infective Medications Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global OTC Anti-Infective Medications Market Perspective (2021-2032)
- 5.2 Global OTC Anti-Infective Medications Growth Trends by Region
- 5.2.1 Global OTC Anti-Infective Medications Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 OTC Anti-Infective Medications Historic Market Size by Region (2021-2026)
- 5.2.3 OTC Anti-Infective Medications Forecasted Market Size by Region (2027-2032)
- 5.3 OTC Anti-Infective Medications Market Dynamics
- 5.3.1 OTC Anti-Infective Medications Industry Trends
- 5.3.2 OTC Anti-Infective Medications Market Drivers
- 5.3.3 OTC Anti-Infective Medications Market Challenges
- 5.3.4 OTC Anti-Infective Medications Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top OTC Anti-Infective Medications Players by Revenue
- 6.1.1 Global Top OTC Anti-Infective Medications Players by Revenue (2021-2026)
- 6.1.2 Global OTC Anti-Infective Medications Revenue Market Share by Players (2021-2026)
- 6.2 Global OTC Anti-Infective Medications Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of OTC Anti-Infective Medications Head Office and Area Served
- 6.4 Global OTC Anti-Infective Medications Players, Product Type & Application
- 6.5 Global OTC Anti-Infective Medications Manufacturers Established Date
- 6.6 Global OTC Anti-Infective Medications Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America OTC Anti-Infective Medications Market Size (2021-2032)
- 7.2 North America OTC Anti-Infective Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America OTC Anti-Infective Medications Market Size by Country (2021-2026)
- 7.4 North America OTC Anti-Infective Medications Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe OTC Anti-Infective Medications Market Size (2021-2032)
- 8.2 Europe OTC Anti-Infective Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe OTC Anti-Infective Medications Market Size by Country (2021-2026)
- 8.4 Europe OTC Anti-Infective Medications Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific OTC Anti-Infective Medications Market Size (2021-2032)
- 9.2 Asia-Pacific OTC Anti-Infective Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific OTC Anti-Infective Medications Market Size by Country (2021-2026)
- 9.4 Asia-Pacific OTC Anti-Infective Medications Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America OTC Anti-Infective Medications Market Size (2021-2032)
- 10.2 South America OTC Anti-Infective Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America OTC Anti-Infective Medications Market Size by Country (2021-2026)
- 10.4 South America OTC Anti-Infective Medications Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa OTC Anti-Infective Medications Market Size (2021-2032)
- 11.2 Middle East & Africa OTC Anti-Infective Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa OTC Anti-Infective Medications Market Size by Country (2021-2026)
- 11.4 Middle East & Africa OTC Anti-Infective Medications Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abbott
- 12.1.1 Abbott Company Information
- 12.1.2 Abbott Business Overview
- 12.1.3 Abbott Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.1.4 Abbott OTC Anti-Infective Medications Product Portfolio
- 12.1.5 Abbott Recent Developments
- 12.2 Sanofi
- 12.2.1 Sanofi Company Information
- 12.2.2 Sanofi Business Overview
- 12.2.3 Sanofi Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.2.4 Sanofi OTC Anti-Infective Medications Product Portfolio
- 12.2.5 Sanofi Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.3.4 Novartis OTC Anti-Infective Medications Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Merck
- 12.4.1 Merck Company Information
- 12.4.2 Merck Business Overview
- 12.4.3 Merck Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.4.4 Merck OTC Anti-Infective Medications Product Portfolio
- 12.4.5 Merck Recent Developments
- 12.5 Roche
- 12.5.1 Roche Company Information
- 12.5.2 Roche Business Overview
- 12.5.3 Roche Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.5.4 Roche OTC Anti-Infective Medications Product Portfolio
- 12.5.5 Roche Recent Developments
- 12.6 Pfizer
- 12.6.1 Pfizer Company Information
- 12.6.2 Pfizer Business Overview
- 12.6.3 Pfizer Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.6.4 Pfizer OTC Anti-Infective Medications Product Portfolio
- 12.6.5 Pfizer Recent Developments
- 12.7 GlaxoSmithKline
- 12.7.1 GlaxoSmithKline Company Information
- 12.7.2 GlaxoSmithKline Business Overview
- 12.7.3 GlaxoSmithKline Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.7.4 GlaxoSmithKline OTC Anti-Infective Medications Product Portfolio
- 12.7.5 GlaxoSmithKline Recent Developments
- 12.8 Optimer Pharmaceuticals
- 12.8.1 Optimer Pharmaceuticals Company Information
- 12.8.2 Optimer Pharmaceuticals Business Overview
- 12.8.3 Optimer Pharmaceuticals Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.8.4 Optimer Pharmaceuticals OTC Anti-Infective Medications Product Portfolio
- 12.8.5 Optimer Pharmaceuticals Recent Developments
- 12.9 Novabay Pharmaceuticals
- 12.9.1 Novabay Pharmaceuticals Company Information
- 12.9.2 Novabay Pharmaceuticals Business Overview
- 12.9.3 Novabay Pharmaceuticals Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.9.4 Novabay Pharmaceuticals OTC Anti-Infective Medications Product Portfolio
- 12.9.5 Novabay Pharmaceuticals Recent Developments
- 12.10 NanoViricides
- 12.10.1 NanoViricides Company Information
- 12.10.2 NanoViricides Business Overview
- 12.10.3 NanoViricides Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.10.4 NanoViricides OTC Anti-Infective Medications Product Portfolio
- 12.10.5 NanoViricides Recent Developments
- 12.11 MerLion Pharma
- 12.11.1 MerLion Pharma Company Information
- 12.11.2 MerLion Pharma Business Overview
- 12.11.3 MerLion Pharma Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.11.4 MerLion Pharma OTC Anti-Infective Medications Product Portfolio
- 12.11.5 MerLion Pharma Recent Developments
- 12.12 Bristol-Myers Squibb
- 12.12.1 Bristol-Myers Squibb Company Information
- 12.12.2 Bristol-Myers Squibb Business Overview
- 12.12.3 Bristol-Myers Squibb Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.12.4 Bristol-Myers Squibb OTC Anti-Infective Medications Product Portfolio
- 12.12.5 Bristol-Myers Squibb Recent Developments
- 12.13 Basilea Pharmaceutica
- 12.13.1 Basilea Pharmaceutica Company Information
- 12.13.2 Basilea Pharmaceutica Business Overview
- 12.13.3 Basilea Pharmaceutica Revenue in OTC Anti-Infective Medications Business (2021-2026)
- 12.13.4 Basilea Pharmaceutica OTC Anti-Infective Medications Product Portfolio
- 12.13.5 Basilea Pharmaceutica Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst